EUVIMEDEUVIMED entdecken
Crossref

Dexamethasone-Appended Activatable Prodrug Overcoming Multidrug Resistance

Jungryun Kim, Chong Hu, Paramesh Jangili iD, Chu Tang, Fu Wang iD, Jong Seung Kim iD

Journal of Medicinal Chemistry · 2025

DOI: 10.1021/acs.jmedchem.5c02565 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Jungryun Kim und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Korea University, Seoul 02841, Korea. Hauptthemen laut MEDLINE: Prodrugs, Dexamethasone, Drug Resistance, Neoplasm, Drug Resistance, Multiple. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: National Research Foundation of Korea, Natural Science Basic Research Program of Shaanxi Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Residual tumor cells that persist after chemotherapy, even in minimal quantities, often exhibit drug resistance and increased invasiveness, potentially leading to tumor metastasis and recurrence. This study introduces a novel reactive oxygen species (ROS)-responsive prodrug, Dex-Dox, designed to overcome multidrug resistance (MDR) in tumor cells. The prodrug is composed of the anti-inflammatory glucocorticoid dexamethasone (Dex) conjugated with doxorubicin (Dox), a widely used antitumor agent, through an oxidative stress-responsive linker. Our in vitro findings revealed that, while Dex alone did not exhibit antitumor activity, Dex-Dox significantly enhanced drug sensitivity, promoting apoptosis and inhibiting angiogenesis in drug-resistant cells. Furthermore, in vivo therapeutic evaluations and histological analyses demonstrated that Dex-Dox substantially reduced tumor volumes, especially in a Dox-resistant tumor mouse model, underscoring its potential as an effective strategy against MDR in cancer therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProdrugsDexamethasoneDrug Resistance, NeoplasmDrug Resistance, MultipleDoxorubicinAntineoplastic AgentsAnimalsHumansMiceApoptosisReactive Oxygen SpeciesCell Line, TumorMice, Inbred BALB CMice, NudeXenograft Model Antitumor Assays

Substanzen

ProdrugsDexamethasoneDoxorubicinAntineoplastic AgentsReactive Oxygen Species

Autor:innen und Institutionen

  • Department of Chemistry, Korea University, Seoul 02841, Korea.
  • Engineering Research Center of Molecular and Neuro Imaging, Ministry of Education, School of Life Science and Technology, Xidian University, Xi'an, Shaanxi 710126, China.
  • Institute of Medical Engineering, School of Basic Medical Sciences, Xi'an Jiaotong University, Xi'an 710061, China.

ORCID-Profile: Paramesh Jangili, Fu Wang, Jong Seung Kim

Förderung

  • National Research Foundation of Korea
  • Natural Science Basic Research Program of Shaanxi Province
  • National Natural Science Foundation of China

Zitieren

APA

Kim, J., Hu, C., Jangili, P., Tang, C., Wang, F., & Kim, J. S. (2025). Dexamethasone-Appended Activatable Prodrug Overcoming Multidrug Resistance. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c02565

Vancouver

Kim J, Hu C, Jangili P, Tang C, Wang F, Kim JS. Dexamethasone-Appended Activatable Prodrug Overcoming Multidrug Resistance. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.5c02565

BibTeX
@article{Kim2025,
  author = {Kim, Jungryun and Hu, Chong and Jangili, Paramesh and Tang, Chu and Wang, Fu and Kim, Jong Seung},
  title = {Dexamethasone-Appended Activatable Prodrug Overcoming Multidrug Resistance},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  doi = {10.1021/acs.jmedchem.5c02565}
}
Kostenlos starten →